Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595398 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
A Phase 3 study of Uveitis and Uveitis, Posterior, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT02595398 is a Phase 3 study of Uveitis and Uveitis, Posterior that has completed, run by Clearside Biomedical. The registered enrollment target is 160 participants, below the 609-participant average among 19 other Uveitis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02595398, a Phase 3 study of Uveitis and Uveitis, Posterior, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.
Conditions Studied
Interventions
- DRUG Sham Procedure
- DRUG 4mg CLS-TA Suprachoriodal Injection
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills
- USC Eye Institute - Los Angeles
- Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
- Orange County Retina Medical Group - Santa Ana
Illinois
- Northwestern University - Chicago
- University of Illinois at Chicago - Chicago
- Illinois Retina Associates, S.C. - Oak Park
Arizona
- Retinal Consultants of Arizona - Phoenix
- Retina Centers, PC - Tucson
Colorado
- University of Colorado - Aurora
- Colorado Retina Associates - Golden
Florida
- Retina Group of Florida - Fort Lauderdale
- Center for Retina and Macular Disease - Lakeland
Georgia
- Emory Eye Center Emory University - Atlanta
- Marietta Eye Clinic - Marietta
Maryland
- Elman Retina Group, PA - Baltimore
- The Retina Group of Washington - Chevy Chase
Indiana
- Midwest Eye Retina Practicing at Midwest Eye Institute - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-11-17 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595398
The ClinicalTrials.gov registry entry for NCT02595398 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 19 other Uveitis trials with a reported enrollment target (74% lower). The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT02595398 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT02595398 about?
NCT02595398 is a clinical study titled "Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis". The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.
What is the current status of trial NCT02595398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2015-11-17. Estimated completion is 2018-01-18.
What conditions does trial NCT02595398 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior, Panuveitis.
What interventions are being tested in trial NCT02595398?
The interventions under investigation include: Sham Procedure (DRUG), 4mg CLS-TA Suprachoriodal Injection (DRUG).
Who is sponsoring clinical trial NCT02595398?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02595398 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Difluprednate in the Treatment of Uveitis
COMPLETED · Phase 3
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
COMPLETED · Phase 3
-
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
COMPLETED · Phase 3
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.